Matinas BioPharma Holdings (MTNB) Non Operating Investment Income (2019 - 2022)

Matinas BioPharma Holdings (MTNB) has 4 years of Non Operating Investment Income data on file, last reported at $1.8 million in Q4 2022.

• Non Operating Investment Income for Q4 2022 came in at $1.8 million, up 373929.79% year-over-year; the trailing twelve-month figure through Dec 2022 was $3.5 million (up 162.88% YoY), and the FY2023 annual result was $484000.0, down 86.14% from the prior year.
• Non Operating Investment Income climbed to $1.8 million in Q4 2022 per MTNB's latest filing, from $1.7 million in the prior quarter.
• Over five years, Non Operating Investment Income peaked at $1.8 million in Q4 2022 and troughed at -$470.0 in Q4 2021.
• A 4-year average of $1.1 million and a median of $1.2 million in 2020 frame the typical range for Non Operating Investment Income.
• The sharpest annual moves came in 2021 and 2022: Non Operating Investment Income grew 23.78% in 2021, then jumped 373929.79% in 2022.
• A 4-year view of Non Operating Investment Income shows it stood at $1.0 million in 2019, then grew by 6.57% to $1.1 million in 2020, then sank by 100.04% to -$470.0 in 2021, then jumped by 373929.79% to $1.8 million in 2022.
• Business Quant data shows MTNB's Non Operating Investment Income at $1.8 million in Q4 2022, $1.7 million in Q1 2022, and -$470.0 in Q4 2021.